AI in Biotech: Hype vs Reality
AI promises to transform biotech, but real-world results are more incremental. A practical perspective on AI in drug discovery, genomics, diagnostics, and lab automation.
Resources
Industry developments, trends and commentary.
9 of 12 resources
AI promises to transform biotech, but real-world results are more incremental. A practical perspective on AI in drug discovery, genomics, diagnostics, and lab automation.
Unfiltered truths, hidden risks, and real data behind life sciences R&D in North America. Discover the facts nobody else is sharing—read the full report now
This article explores the complexities of biosimilars, including their development process, regulatory challenges, economic impact, and future prospects. It highlights the potential of biosimilars to reduce healthcare costs and increase patient access to biologic therapies, providing valuable insights for biopharmaceutical and academic researchers.
A look back at major biotechnology deals and trends from the decade leading up to the 2025 J.P. Morgan Healthcare Conference.
It is clear that the failure of Silicon Valley Bank (SVB) has had a significant impact on the biotech industry, especially in the greater Boston area where many startups rely on the bank's lending services. The sudden closure of the bank and the risk of severe losses for large depositors had caused panic among clients, leading to a bank run and further financial losses for the bank.The impact of SVB's failure on biotech companies goes beyond just the financial losses. The biotech industry has already been going through a challenging period of layoffs and budget cuts, and the loss of a major lending institution like SVB could exacerbate these challenges. However, the quick response from federal regulators and regional agencies in fully protecting deposits and providing relief measures is a positive development.
Laboratories depend on research reagents. Time and resources are wasted sourcing commercial DNA, RNA and recombinant proteins and antibodies. Gain a better understanding about reagents for cellular and molecular biological experiments that advance drug discovery
As a headline, it is tough to compete with the appeal of the COVID controversy. This can be especially challenging for biotechnology and life science organizations, considering the industry’s role in the pandemic response. In fact, a significant number of those organizations continued their non-COVID research. We were fortunate to work with various laboratory groups and their fascinating research. Many of which achieved significant progress during the pandemic. Read about their compelling research, unrelated to COVID and more in our article
A 2019 opinion article on the limits of reagent search tools and the information researchers need when sourcing recombinant proteins.
Commercializing synthetic research reagents is very complex in the life science industry. Companies are attempting to address the challenges of sourcing proper reagents by way of ecommerce innovation and are faced with the same bottleneck. Discover what factors are limiting product diversity in research.
A 2019 perspective on the challenges of sourcing difficult-to-express recombinant proteins, including kbDNA’s protein work at the time.
ssDNA, siRNA, gRNA, LNA, BNA & more novel breakthroughs in oligonucleotides for life science research and drug discovery. Discover how versatile synthesis is innovating automated synthesis and shaping the future of biotechnology.